Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T · 1 trial · 2 indications
Determine if treatment with autologous genetically modified T cells, (MAGE A10ᶜ⁷⁹⁶T ) is safe and tolerable through assessment of DLTs, AEs, including SAEs; laboratory assessments, including chemistry, hematology, and coagulation; cardiac and pulmonary assessments, including ECG and troponin.
| Arm | Type | Description |
|---|---|---|
| Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T | BIOLOGICAL | - |
Key Inclusion Criteria: 1. Subject has histologically or cytologically confirmed diagnosis of advanced non-small cell lung cancer (stage IIIB or IV) or recurrent disease 2. Subject has received at least one line of prior therapy 3. Subjects with known epidermal growth factor receptor (EGFR) mutatio...
Top 20 of 87 competitors
Autologous genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T is an investigational cell therapy being developed by Adaptimmune Therapeutics PLC for non-small cell lung cancer. It is a biologic made from a patient's own T cells that have been genetically modified, and it is being studied in biomarker-selected patients with advanced NSCLC.
MAGEA10ᶜ⁷⁹⁶T is being studied for the treatment of advanced non-small cell lung cancer, including carcinoma, in adults 18 years and older. The Phase 1 trial enrolled biomarker-selected patients, meaning eligibility depended on a defined biomarker rather than an unselected NSCLC population.
MAGEA10ᶜ⁷⁹⁶T is an autologous T-cell product genetically modified to express a T-cell receptor directed at MAGE-A10, a cancer-testis antigen. The target class is an exogenous gene introduced into the patient's T cells, so the therapy's activity depends on that engineered receptor recognizing MAGE-A10-expressing tumor cells.
MAGEA10ᶜ⁷⁹⁶T is being developed by Adaptimmune Therapeutics PLC, which trades under the ticker ADAPY. The company is the sponsor of the Phase 1 study of this autologous genetically modified T-cell therapy in advanced non-small cell lung cancer.
MAGEA10ᶜ⁷⁹⁶T is in Phase 1 development and is investigational; it is not an approved therapy. The single Phase 1 trial, NCT02592577, has been completed and enrolled 28 patients. No active trials of this asset are currently listed.
MAGEA10ᶜ⁷⁹⁶T has been studied in one Phase 1 trial, NCT02592577, titled MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC. The completed study enrolled 28 patients across the United States, Canada, Spain, and the United Kingdom. It was an uncontrolled, non-randomized, open-label study without double blinding.